Jim Mullen, Editas Medicine

Ex-Bio­gen CEO Jim Mullen steps back to the helm of a biotech, and once again he has a crit­i­cal chal­lenge to con­front

A decade af­ter he was pushed out of the top post at Bio­gen by a gang of ac­tivists, Jim Mullen is step­ping back up to the helm of a biotech — this time look­ing to make his­to­ry in gene edit­ing.

Ed­i­tas put out the word this morn­ing that Mullen, who has been chair­man of the com­pa­ny, will take the CEO po­si­tion as Cindy Collins steps aside on Feb­ru­ary 15. Mullen is the third CEO to run the com­pa­ny since he was named chair­man in 2018.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.